How Labour’s UK generic drugs plan could have been better
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Medtronic bets on flexibility for its surgical robots
The long-awaited robotic surgery system is designed to open up the market.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Bayer could become the latest casualty of Roche’s targeted pricing
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Mustang Bio sets its sights on 2021 approval
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
No news equals bad news for Nabriva and Heron
Manufacturing issues prompt the US regulator to knock back projects from Nabriva and Heron Therapeutics, both of which insist that the problems are easily solvable.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.